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Abstract
Background: To identify the association between somatic ataxia-telangiectasia mutated (ATM) mutations and
improved radio-sensitivity, we retrospectively reviewed next-generation sequencing data from patients diagnosed
with isocitrate dehydrogenase (IDH)-wildtype high-grade glioma.
Methods: We included 39 individuals with (IDH)-wildtype high-grade glioma (diffuse astrocytoma n = 2, anaplastic
astrocytoma n = 10, and glioblastoma n = 27) not subjected to gross tumor resection and undergoing radiation
therapy with a median total dose of 60 Gy in 30 fractions. The mutational status of the ATM gene was obtained
through next-generation sequencing using a TruSight Tumor 170 cancer panel. Disease progression was defined
according to the Response Assessment in Neuro-Oncology (RANO) criteria as well as neurologic and clinical
findings.
Results: Among the 39 samples, ATM mutations (ATM mut(+)) were detected in 26% of cases (n = 10). No
significant differences were observed in the characteristics of the patients or tumors. Among the 10 patients in the
ATM mut(+) group, there were 6 patients with glioblastoma and 4 patients with anaplastic astrocytoma. Most
mutations were missense mutations (n = 8, 80%). With a median follow-up of 16.5 mo (interquartile range, 11.4–19.8),
ATM mut(+) exhibited 1-year in-field control of 100% compared with 44.1% in the ATM mut(−) group (p = 0.002). There
was no difference in the out-field control rate or overall survival between the two groups (p = 0.861 and p = 0.247,
respectively).
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Conclusions: Our results demonstrated that ATM mutations might be involved in the increased radio-sensitivity with
excellent in-field control despite the aggressive nature of IDH-wildtype high-grade glioma. Further studies are
necessary to uncover the potential role of ATM as a biomarker and candidate therapeutic target in high-grade gliomas.
Keywords: ATM, IDH-wild type high-grade glioma, Radiosensitivity, Next-generation sequencing, Radiation therapy
Background
Isocitrate dehydrogenase (IDH)-wildtype high-grade
glioma (diffuse astrocytoma, anaplastic astrocytoma,
and glioblastoma multiforme [GBM]), being an ag-
gressive brain tumor, has been correlated with poor
prognosis despite the best trimodality treatment ap-
proaches (surgery, chemotherapy, and radiation ther-
apy (RT)). This poor prognosis has been attributed to
the intrinsic radio- and chemo-resistance of the
tumor [1]. Although there are several clinical and
molecular factors known to be prognostic factors for
high-grade glioma, including methylation of O-6-
methylguanine-DNA methyltransferase (MGMT) pro-
moter, age, involvement of the subventricular zone
(SVZ), extent of resection, and sex [2], most patients
are treated with a uniform adjuvant treatment ap-
proach (i.e., one-size-fits-all).
The ataxia-telangiectasia mutated (ATM) gene encodes
a serine/threonine protein kinase known to be activated
by autophosphorylation upon DNA double-strand
breaks arising from ionizing radiation. The prevalence of
ATM mutations (ATM mut(+)) in high-grade glioma is
known to be less than 5% [3]; hence, owing to this rarity,
there have been no clinical reports on such patients.
Similar to the approach employing a PARP inhibitor tar-
geting BRCA1 mutations in breast and ovarian cancers
[4], several preclinical studies on the inhibition of ATM
have been performed to enhance radio-sensitivity in
other solid tumors [5, 6] and high-grade gliomas [7–10].
Rainey et al. discovered that transient inhibition of ATM
by chemicals (CP466722) sensitizes HeLa cells and cells
expressing BCR-Abl to ionizing radiation [6]. Recently,
Golding et al. demonstrated that dynamic ATM inhib-
ition with sub-micromolar concentrations of KU-60019
slightly increased RT-induced cell killing in human glio-
blastoma cells [8]. These studies intrigued many physi-
cians to identify the clinical significance of ATM mut(+)
in real practice.
With the emergence of state-of-the-art sequencing,
next-generation sequencing (NGS) [11], physicians have
easy access to the ATM mutational status of every pa-
tient. In this context, we undertook a retrospective ana-
lysis of NGS data to address the radio-sensitivity of
ATM mut(+) and its impact on clinical outcomes in
patients with IDH-wildtype high-grade glioma.
Methods
Patient selection
As NGS data for gliomas have been utilized in our insti-
tution from 2017, patients with newly diagnosed WHO
grade II with IDH-wildtype, WHO grade III and IV type
gliomas, according to the new 2016 WHO classification,
were screened between June 2017 and December 2018.
Accordingly, we screened for patients treated with RT
following surgery and patients with available NGS data
(n = 144). Patients were excluded from the study if one
of the following criteria was met: (1) they had undergone
gross total removal of the tumor, and thus it was not
possible to investigate the response of the residual tumor
to RT (n = 66); (2) they had been previously diagnosed
with a primary CNS tumor (n = 15); (3) they had tumors
with IDH mutations (n = 9); (4) they had undergone
hypofractionated RT (n = 2); (5) peritumoral edema was
not included in RT fields (n = 5); (6) they could not pro-
vide follow-up images (n = 5); and (7) they could not
complete RT (n = 3). Finally, 39 patients, including 10
patients with ATM mutations (ATM mut(+) group) and
29 patients without ATM mutations (ATM mut(−)
group), were included in our cohort. The study protocol
was approved by the institutional review board (No.4–
2019-0009), and the requirement for the provision of in-
formed consent was waived because of the retrospective
nature of this study.
Multi-modal treatments
Treatments and follow-up for every patient were per-
formed by a multidisciplinary neuro-oncology board, in-
cluding neurosurgeons, radiation oncologists, neuro-
radiologists, neuropathologists, and medical oncologists
[2]. All patients were evaluated based on perioperative
and follow-up magnetic resonance images (MRI) and
clinical symptoms. The involvement of the SVZ was
assessed via preoperative MRI according to a standard-
ized spatial classification [12]. Navigation-guided surgery
following the maximal safe resection protocol was per-
formed for all patients, except for those who underwent
stereotactic biopsy. The extent of surgery was evaluated
using immediate postoperative gadolinium-enhanced
T1-weighted MRI obtained within 48 h after surgery and
then categorized as total (absence of visible contrast-
enhanced portion), subtotal (at least 90% of the tumor
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removed), partial (less than 90% of the tumor removed),
or biopsy (in case of stereotactic biopsy) [13].
Conventional fractionated RT with a median total dose
of 60 Gy (interquartile range, IQR: 60.0–60.0) was ap-
plied in 30 fractions to the gross tumor volume. With
postoperative MRI, both the resection cavity and re-
sidual tumor were included in the gross tumor volume.
The clinical target volume was delineated to include the
peritumoral edema with a 1- or 1.5-cm margin on T2-
weighted fluid-attenuated inversion recovery postopera-
tive MRI, and a median total dose of 49.5 Gy (IQR:
48.0–51.0) in 30 fractions was then applied to the clin-
ical target volume [14, 15]. Following the treatment
strategy followed at our institution, there was no differ-
ence in the dose prescription of the protocol according
to pathology: all patients were treated with intensity-
modulated RT using Tomotherapy (Hi-Art TomoTher-
apy; Accuray, Sunnyvale, CA, USA).
In the case of patients with GBM, during RT, all pa-
tients concomitantly underwent a daily administration of
temozolomide (75 mg/m2 of body surface area per day,
7 days per week, from the first to the last day of RT),
followed by the administration of adjuvant temozolo-
mide (150–200 mg/m2 for 5 days during each 28-day
cycle). Regarding patients with anaplastic astrocytoma
and WHO grade II with IDH-wildtype, 6 cycles of adju-
vant procarbazine, lomustine, and vincristine (oral
lomustine; 110 mg/m2 on day 1; oral procarbazine: 60
mg/m2 per d from day 8 to day 21; and intravenous vin-
cristine: 1.4 mg/m2 on day 8 and 29) were administered
every 6 weeks for 9 months.
Molecular analysis
Representative formalin-fixed, paraffin-embedded tissues
were analyzed by targeted NGS using the commercially
available TruSight Tumor 170 panel (Illumina, Inc., San
Diego, CA, USA). Detailed methods for the procedure of
sequencing and data analysis have been previously de-
scribed [16, 17]. In the obtained NGS data, along with
ATM mutations, we identified other frequent mutations
found in gliomas, such as mutations in the Breast Can-
cer susceptibility gene1/2 (BRCA1/2), phosphatase and
tensin homolog (PTEN), telomerase reverse transcriptase
(TERT), and tumor protein p53 (TP53) genes. The DNA
methylation status of the MGMT promoter was also ex-
amined [18]. Additionally, we stratified patients based
on the consensus guidelines from the Consortium to In-
form Molecular and Practical Approaches to CNS
Tumor Taxonomy (cIMPACT-NOW) for the identifica-
tion of gliomas appearing histologically as WHO grade
II or III with molecular features of GBM using the fol-
lowing criteria: (1) amplification of epidermal growth
factor receptor (EGFR) (n = 1), (2) combined whole
chromosome 7 gain and whole chromosome 10 loss, or
(3) mutation of the TERT promoter (n = 5) [19].
Follow-up
Follow-up of all patients was performed until death or
time of analysis. Most patients underwent MRI 1 month
after the planned RT as well as every 3 months for the
first 2 years, and every 6 to 12months thereafter accord-
ing to institutional policy. Disease progression was de-
fined using the Response Assessment in Neuro-
Oncology (RANO) criteria [20] as well as neurologic and
clinical findings. All patients suspected of having pro-
gressive disease were determined as exhibiting progres-
sive disease after discussion and joint decision made by
the multidisciplinary team. Either in-field or out-field
failure was defined based on the relationship between
the RT field (within the region for 95% of the prescribed
dose) and the volume of the recurrence tumor assessed
by MRI .
Statistical analysis
Parsons’ Chi-square or Fisher’s exact test were used to
analyze categorical variables, whereas the Mann-
Whitney U test (non-normally distributed data) was
used to compare continuous variables when comparing
differences in the characteristics of patients and treat-
ments between the two groups. All events (including in-
field failure, out-field failure, and death) were measured
from the day of diagnosis (day of surgery) to the time of
the event. The Kaplan-Meier method was performed to
estimate the in-field, out-field, and overall survival (OS)
rates with the log-rank test used to assess prognostic sig-
nificance. Univariable analyses of in-field and out-field
control as well as OS were performed using Cox regres-
sion analysis. Further multivariable analysis was not per-
formed because there was no statistically significant
factor identified in the univariable analysis. A p-value <
0.05 was considered statistically significant. Statistical
analyses were performed using SPSS (version 25.0.0;
IBM Corp., Armonk, NY, USA) and R (version 3.6.2; R
Foundation for Statistical Computing, Vienna, Austria;
https://www.R-project.org/) software.
Results
The median age at diagnosis was 59 years (IQR: 48–63),
and most patients presented with a Karnofsky perform-
ance scale (KPS) score ≤ 80. Perioperative MRI revealed
that 87.2% of tumors were located in the SVZ, and
48.7% of patients underwent subtotal removal. Methyla-
tion of the MGMT promoter was observed in 61.5% of
patients. There was no significant difference in the char-
acteristics of the patients and treatments between the
ATM mut(+) and ATM mut(−) groups (Table 1). In
addition, there was no difference in the frequency of
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mutations in other genes (Additional file 1). Detailed in-
formation on each patient with an ATM mutation is
listed in Table 2. Missense mutations (8 patients, 80%)
were the most common mutations in the ATM mut(+)
group. There were six patients diagnosed with GBM and
four patients with IDH-wildtype anaplastic astrocytoma.
Based on preoperative MRI, the involvement of the SVZ
(9 patients, 90.0%) and the presence of gliomatosis (6 pa-
tients, 60.0%) were frequently observed in the ATM
mut(+) group.
The median follow-up for all patients was 16.5 mo
(IQR: 11.4–19.8), and there was no difference in the
follow-up period between the two groups (ATM mut(+):
18.0 mo (IQR: 11.4–20.8); ATM mut(−): 15.5 mo (IQR:
10.0–19.2), p = 0.645). Patients with ATM mut(+)
showed no in-field failure compared with the ATM
mut(−) group (1-y in-field control rate: 100.0% vs. 44.1%,
p = 0.002, Fig. 1a). Conversely, there was no difference in
the out-field failure between the two groups (1-y out-
field control rate: 71.4% vs. 51.9%, p = 0.861, Fig. 1b). Of
Table 1 Patient and treatment characteristics
Total ATM mut(−) ATM mut(+) p-value
N = 39 N = 29 N = 10
Median age [IQR], years 59.0 [47.5;63.0] 60.0 [52.0;64.0] 49.0 [37.0;59.0] 0.071
< 60 years, n (%) 22 (56.4) 14 (48.3) 8 (80.0) 0.169
≥ 60 years, n (%) 17 (43.6) 15 (51.7) 2 (20.0)
Sex, n (%) 0.727
Male 20 (51.3) 14 (48.3) 6 (60.0)
Female 19 (48.7) 15 (51.7) 4 (40.0)
Preoperative KPS, n (%) 0.580
≤ 80 28 (71.8) 22 (75.9) 6 (60.0)
90–100 11 (28.2) 7 (24.1) 4 (40.0)
Subventricular zone, n (%) 1.000
Free 5 (12.8) 4 (13.8) 1 (10.0)
Involvement 34 (87.2) 25 (86.2) 9 (90.0)
Gliomatosis, n (%) 0.515
No 21 (53.8) 17 (58.6) 4 (40.0)
Yes 18 (46.2) 12 (41.4) 6 (60.0)
Pathology*, n (%) 0.380
Diffuse astrocytoma 2 (5.1) 2 (6.9) 0 (0.0)
Anaplastic astrocytoma 10 (25.7) 6 (20.7) 4 (40.0)
Glioblastoma 27 (69.2) 21 (72.4) 6 (60.0)
MGMT promoter, n (%) 1.000
Unmethylated 15 (38.5) 11 (37.9) 4 (40.0)
Methylated 24 (61.5) 18 (62.1) 6 (60.0)
Median Ki67 index [IQR], % 15.0 [6.5;26.2] 15.0 [6.5;27.5] 17.5 [7.5;30.0] 0.617
< 15%, n (%) 16 (41.0) 12 (41.4) 4 (40.0) 1.000
≥ 15%, n (%) 23 (59.0) 17 (58.6) 6 (60.0)
Extent of resection, n (%) 0.562
Biopsy 2 (5.1) 2 (6.9) 0 (0.0)
Partial removal 18 (46.2) 14 (48.3) 4 (40.0)
Subtotal removal 19 (48.7) 13 (44.8) 6 (60.0)
Median total RT dose [IQR], Gy 60.0 [60.0;60.0] 60.0 [60.0;60.0] 60.0 [60.0;60.0] 0.600
Median total RT fractions [IQR], fx 30.0 [30.0;30.0] 30.0 [30.0;30.0] 30.0 [30.0;30.0] 0.631
Abbreviations: IQR interquartile range, ATM ataxia-telangiectasia mutated gene, mut mutation, KPS Karnofsky performance status, MGMT O[6]-methylguanine-DNA
methyltransferase, RT radiation therapy, Gy gray, fx fractions
* Pathology refers to the WHO grade
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23 out-field failures, 6 failures (60.0% of ATM mut(+))
occurred in the ATM mut(+) group and 17 (58.6% of
ATM mut(−)) in the ATM mut(−) group. In addition,
out-field failures in the ATM mut(+) group were ob-
served to have developed at a median of 15.4 mo (IQR:
11.6–18.9) after diagnosis. In addition, 3 patients died of
progressive disease in the ATM mut(+) group with a 2-y
OS rate of 32.1%, which was comparable to that of the
ATM mut(−) group (39.9%, p = 0.247, Fig. 1c). Using
Cox regression univariable analysis, we noted that only
the BRCA mutation status was associated with worse
out-field control (Hazard Ratio, 2.44) and poor OS
(Hazard Ratio, 2.78, Table 3).
In subsequent analysis employing the recommended
diagnostic criteria for the molecular features of glioblast-
oma according to cIMPACT-NOW (n = 33), ATM
mut(+) (n = 6) was shown to be associated with better
in-field control than ATM mut(−) (n = 27) (1-y in-field
Table 2 Detailed information on patients harboring the ATM mutation





















VAF (%) 43.01 53.22 46.3 79.92 11.8 25.88 92.49 6.45 5.08 0.369
Amino acid change p.R2832H p.R924O p.K92T p.P2974L p.L822S p.L2946Nfs*9 p.K92T p.L413I p.S28212Vfs*3 p.P260T
Sequence change c.8495G > A c.2771G > A c.275A > C c.8921C > T c.2465 T > C c.8835_8836delGT c.275A > C c.1237C > A c.8432dupA c.778C > A
Age, years 63 51 47 35 32 43 37 58 63 59
Sex Male Female Female Female Male Male Female Male Male Male
KPS 70 90 80 90 80 80 90 80 100 60
Pathology GBM GBM GBM GBM GBM GBM AA, IDH-WT AA, IDH-WT AA, IDH-WT AA, IDH-WT
MGMT promoter
methylation
(−) (+) (+) (−) (+) (+) (−) (−) (+) (+)
SVZ involvement Yes None Yes Yes Yes Yes Yes Yes Yes Yes
Gliomatosis No No Yes Yes No Yes No Yes Yes Yes
Extent of resection Subtotal Subtotal Partial Subtotal Subtotal Subtotal Partial Subtotal Partial Subtotal
Total RT dose, Gy 60 60 60.2 60 60 60 60 60.2 60 60
PD Yes Yes No Yes No No No Yes No No
PD interval, months 11.6 18.9 18.0 14.4 15.4
Progression site* Out-field Out-field Out-field Out-field Out-field
Salvage treatment CTx Re-RT BSC BSC Re-RT
Follow-up, months 22.7 19.8 20.8 15.0 8.1 11.4 18.7 17.3 19.2 11.1
Survival Dead Alive Dead Dead Alive Alive Alive Alive Alive Alive
Abbreviations: VAF Variant Allele Frequency, KPS Karnofsky performance status, GBM glioblastoma, AA anaplastic astrocytoma, IDH isocitrate dehydrogenase, WT
wild-type, MGMT O[6]-methylguanine-DNA methyltransferase, SVZ subventricular zone, RT radiation therapy, PD progressive disease, CTx chemotherapy, Re-RT re-
irradiation, BSC best supportive care
* Progression site was defined based on relationship between radiation field and recurrence site
Fig. 1 In-field a and out-field b control rates, and overall survival c of patients according to the mutational status of ATM
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control rate: 100.0% vs. 47.5%, p = 0.021; Fig. 2a,
Additional File 2). The out-field control rate and OS
values were comparable between the ATM mut(+) and
ATM mut(−) groups in tumors with the molecular fea-
tures of glioblastoma (Fig. 2b-c, Additional File 2). Even
in tumors in contact with SVZ, the ATM mut(+) group
was observed to be significantly associated with better
in-field control than ATM mut(−) (1-y in-field control
rate: 100.0% vs. 48.1%, p = 0.003, Additional File 3). In
addition, there were no differences in the out-field con-
trol rate and OS values in tumors involving the SVZ
(p = 0.711, p = 0.433, respectively, Additional File 3).
As the status of BRCA mutations was revealed to func-
tion as a prognostic factor for out-field control and OS,
we performed further subgroup analysis stratified by the
mutational status of ATM and BRCA. Accordingly, pa-
tients with ATM mut(−) and BRCA mut(+) (n = 5)
showed the worst clinical outcomes, with a 1-y in-field
control rate of 20.0%, out-field control rate of 20.0%,
and OS of 20.0% (Fig. 3a-c). In contrast, patients with
ATM mut(+) and BRCA mut(−) (n = 7) were observed to
exhibit statistically better clinical outcomes, with a 1-y
in-field control rate of 100.0% and 2-y OS rate of 40.0%
(p = 0.002, and p = 0.031, respectively). Patients with
ATM mut(+) and BRCA mut(+) (n = 3) showed compar-
able results to the ATM mut(+) and BRCA mut(−) group
(1-y in-field control rate and 1-y OS rate of 100.0%;
p = 0.809 for OS).
Discussion
We investigated the clinical impact of ATM mutations
in patients with intracranial IDH-wildtype high-grade
glioma undergoing RT following incomplete tumor re-
section. Interestingly, although well-known poor prog-
nostic factors, such as either the presence of gliomatosis
or the involvement of the SVZ, were predominant in the
ATM mut(+) group, we observed excellent in-field con-
trol without in-field failure. However, it was shown that
the ATM mut(+) group had no impact on the out-field
area, demonstrating comparable out-field failures to the
ATM mut(−) group. Hence, these clinical results illus-
trated the increased radio-sensitivity of tumors harbor-
ing somatic ATM mutations.
There has been considerable accumulated preclinical
evidence that ATM might play a key role in the response
to ionizing radiation. Preclinical studies on cell lines
from patients with ataxia-telangiectasia syndromes have
demonstrated that these cells exhibit increased sensitiv-
ity to radiation [21, 22]. Similarly, experimental inhib-
ition of ATM was reported to influence cellular
hypersensitivity to radiation [5, 6]. This salutary effect
on the radio-sensitivity of cells following the inhibition
of ATM was recently observed in GBM cell lines [7, 8],
xenograft models of GBM [9], and even patient-derived
xenograft models [10]. However, there have been few
clinical reports agreeing that ATM mut(+) could be a
prognostic biomarker for a favorable response to RT.
Jennifer Ma et al. [23] reported that 8 patients with ex-
tracranial primary disease (nonglial tumors) harboring
ATM mut(+) demonstrated excellent and durable RT re-
sponses with a median local control of 4.62 years; more-
over, only 2 patients exhibited local recurrence.
Especially, 2 patients with breast and non-small cell lung
cancers receiving whole brain RT were observed to re-
lapse at 41.0 and 43.2 months after RT. Additionally, Su
et al. [24] reported the significant benefit of adjuvant RT
in 43 carriers of germline ATM mutations diagnosed
with breast cancer; they reported that 13 patients treated
with RT (not cobalt therapy) remained locally disease-
free, sustaining tolerable toxicities. Recently, we reported
that somatic ATM mutations in solid tumors (except
brain tumors) were related to markedly improved re-
sponses after RT compared with tumors not harboring
ATM mutations: an overall response rate of 61.0% (vs.
24.0% in ATM mut(−) tumors) with a durable response
for a median period of 11 mo (vs. 3 mo in ATM mut(−))
[25]. In the current study, the ATM mut(+) group was
shown to yield excellent in-field control, indicating the
radio-sensitive nature of ATM mutations even in pa-
tients with intracranial high-grade glioma.
Following the generation of radiation-induced double-
strand breaks in the DNA, the ATM gene is known to
control the key signaling pathway in the repair process
of the DNA double-strand break damage [3, 26]. After it
has been recruited to the site of the double-strand break
by the MRE11-RAD50-NBS1 complex, ATM is activated
by autophosphorylation at Ser1981 [27]. Catalytic activa-
tion of ATM is known to subsequently lead to the phos-
phorylation of many downstream effectors involved in
the activation of the G1/S cell-cycle checkpoint arrest
(CHk1 and Chk2) [28], homologous recombination or
non-homologous end-joining repair of DNA [29, 30],
and apoptosis (p53) [31]. Consequently, mutations in
ATM might prevent the repair or restoration of
radiation-induced damaged DNA, resulting in the radio-
sensitivity of cells. Therefore, germline ATM mut(+) is
highly involved in radiation-induced risks from its radio-
sensitivity. Recently, there is an effort to predict individ-
ual response to radiation based on ATM nucleoshuttling
rate [32]. Future investigations to increase the under-
standing of ATM is needed for refinement and develop-
ment models of personalized ionizing radiation
response.
From a clinical point of view, targeting ATM has in-
trigued many researchers and encouraged them to at-
tempt approaches to enhance the radio-sensitivity of
cells. Since then, several ATM inhibitors have been de-
veloped and their in vitro or in vivo radio-sensitivity
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Table 3 Prognostic factors for in-field, out-field control, and overall survival determined using univariable Cox regression analysis
In-field control HR 95% CI P-value
ATM (mut(−) vs. mut(+)) 0.16 0.00–0.48 0.036
Age at diagnosis (< 60 vs. ≥60) 1.02 0.39–2.69 0.966
Sex (male vs. female) 1.09 0.45–2.78 0.857
KPS (90–100 vs. ≤80) 1.44 0.51–4.07 0.496
SVZ (free vs. involvement) 0.97 0.28–3.39 0.974
Gliomatosis (No vs. Yes) 1.34 0.53–3.39 0.534
Extent of resection (subtotal vs. partial/biopsy) 1.15 0.45–2.94 0.767
Pathology (WHO Grade II-III vs. WHO grade IV) 1.47 0.34–6.43 0.606
MGMT promoter (unmethylated vs methylated) 0.59 0.23–1.48 0.260
Ki67 index (< 15% vs. ≥15%) 1.57 0.57–4.32 0.380
BRCA status (wild-type vs mutant) 1.46 0.51–4.19 0.485
PTEN status (wild-type vs mutant) 1.32 0.47–3.72 0.600
TERT status (wild-type vs mutant) 0.93 0.37–2.35 0.873
EGFR amplification (No vs. Yes) 1.98 0.74–5.34 0.176
TP53 status (wild-type vs mutant) 1.39 0.48–4.01 0.546
Out-field control HR 95% CI P-value
ATM (mut(−) vs. mut(+)) 0.92 0.35–2.40 0.862
Age at diagnosis (< 60 vs. ≥60) 1.58 0.68–3.71 0.290
Sex (male vs. female) 0.95 0.40–2.26 0.909
KPS (90–100 vs. ≤80) 1.36 0.55–3.39 0.506
SVZ (free vs. involvement) 1.53 0.45–5.22 0.496
Gliomatosis (No vs. Yes) 2.32 0.96–5.61 0.062
Extent of resection (subtotal vs. partial/biopsy) 0.74 0.32–1.74 0.497
Pathology (WHO Grade II-III vs. WHO grade IV) 2.62 0.93–7.38 0.069
MGMT promoter (unmethylated vs methylated) 0.49 0.21–1.14 0.098
Ki67 index (< 15% vs. ≥15%) 1.35 0.55–3.33 0.511
BRCA status (wild-type vs mutant) 2.44 1.18–6.07 0.035
PTEN status (wild-type vs mutant) 0.96 0.35–2.62 0.939
TERT status (wild-type vs mutant) 0.48 0.20–1.14 0.096
EGFR amplification (No vs. Yes) 3.09 1.09–8.77 0.035
TP53 status (wild-type vs mutant) 1.80 0.67–4.83 0.246
Overall survival HR 95% CI P-value
ATM (mut(−) vs. mut(+)) 0.77 0.27–2.15 0.615
Age at diagnosis (< 60 vs. ≥60) 2.27 0.89–5.84 0.088
Sex (male vs. female) 1.01 0.40–2.54 0.986
KPS (90–100 vs. ≤80) 1.96 0.69–5.57 0.205
SVZ (free vs. involvement) 1.55 0.36–6.79 0.559
Gliomatosis (No vs. Yes) 1.74 0.68–4.46 0.246
Extent of resection (subtotal vs. partial/biopsy) 0.74 0.30–1.84 0.518
Pathology (WHO Grade II-III vs. WHO grade IV) 0.47 0.16–1.43 0.184
MGMT promoter (unmethylated vs methylated) 1.04 0.40–2.72 0.931
Ki67 index (< 15% vs. ≥15%) 1.22 0.48–3.10 0.678
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have been reported [17]. However, to date, no ATM in-
hibitor has yet been clinically used because of the lack of
bioavailability, concerns of potential side-effects, and the
lack of clinical trials. There is an ongoing prospective
phase I trial on the combination of palliative RT and an
ATM inhibitor against solid tumors (NCT03225105). In
addition to the administration of ATM inhibitors as
radio-sensitizers, somatic ATM mutations could also be
applied as intrinsic radio-sensitizers. The advent of NGS
in routine clinical practice might allow ATM to be used
as the sole biomarker for patients treated with RT. Re-
cently, researchers developed a genome-adjusted radi-
ation dose model based on an individualized radio-
sensitivity index with genomic features [33]. Beyond per-
sonalized radiation dose planning, we could cautiously
assume that whole brain or large field RT rather than
focal RT might be an effective personalized treatment
option with excellent in-field control and prolonged sur-
vival in patients with IDH-wildtype ATM mut(+) high-
grade glioma.
In addition, the current study showed that BRCA mu-
tations could be associated with poor outcomes of not
only intracranial control but also OS. Our results ap-
peared to differ to some extent from those demonstrated
on different primary tumors, many of which have
reported the survival benefit of BRCA mutations. To
date, there has not been any clinical evidence supporting
the notion that a somatic BRCA mutation might govern
the prognosis of IDH-wildtype high-grade glioma. Re-
cent studies of germline BRCA1/2 mutations in patients
with breast cancer have suggested that these mutations
have a similar prognosis, though they exhibit different
effects on the efficacy of chemotherapy [34, 35]. Add-
itionally, there have been several reports analyzing the
survival benefit of BRCA1/2 mutations in patients with
ovarian cancer [36]. These data have collectively sup-
ported the relatively better short-term prognosis in pa-
tients carrying BRCA1/2 mutations. In the current study,
a subgroup analysis stratified by the mutational status of
both the BRCA and ATM genes revealed that patients
without any mutation showed comparable outcomes to
the historical data, whereas the ATM mut(−)/BRCA
mut(+) group showed the worst outcomes. The ATM
mut(+) group with or without BRCA mutations showed
comparable results of rates of out-field control and OS,
with the same excellent in-field control. These results
reflected the fact that BRCA might be a target in the
downstream signaling of ATM. Further investigation re-
garding the prognostic impact of BRCA on high-grade
glioma is needed.
Table 3 Prognostic factors for in-field, out-field control, and overall survival determined using univariable Cox regression analysis
(Continued)
BRCA status (wild-type vs mutant) 2.78 1.05–7.36 0.039
PTEN status (wild-type vs mutant) 1.00 0.33–3.04 0.992
TERT status (wild-type vs mutant) 0.88 0.36–2.18 0.785
EGFR amplification (No vs. Yes) 1.78 0.67–4.72 0.249
TP53 status (wild-type vs mutant) 0.42 0.10–1.80 0.241
*The foreparts of the parentheses were set as the reference group
Abbreviations: HR hazards ratio, CI confidence interval, KPS Karnofsky performance status, SVZ subventricular zone, MGMT
O[6]-methylguanine-DNA methyltransferase
Fig. 2 In-field a and out-field b control rates and overall survival c of patients diagnosed with the molecular features of glioblastoma based
on cIMPACT-NOW
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Our study had several limitations. First, this was a
retrospective analysis; thus, the results should be cau-
tiously reviewed. Second, owing to the limited number
of patients, there are issues regarding the statistical in-
significance of the results and the unavailability of multi-
variable analysis to minimize potential confounders.
However, to our knowledge, this study has the largest
clinical data, to date, on tumors with somatic ATM
mutations analyzed by the latest NGS technology. In
addition, a relatively frequent ATM mut(+) in the
current cohort compared to previous report could over-
estimate the potential predictive value of ATM mut(+);
however, the widespread utilization of NGS is expected
to clarify the real-world prevalence of ATM mut(+). An
additional limitation was that this was a single-center
study; however, its consistent treatment strategy of sur-
gery and RT provides another strength to this study.
Lastly, the in-field control rates of the ATM mut(+)
group could have been overestimated owing to the
short-term follow-up of this study. As most patients with
IDH-wildtype high-grade glioma were observed to ex-
perience in-field or out-field failures within 1 year after
diagnosis, the current follow-up period was considered
acceptably reasonable for the analysis of failure patterns.
However, long-term follow-up data based on a larger
number of patients is still needed to efficiently deter-
mine certain effects of ATM mutations.
Conclusions
We demonstrated that ATM mutations in IDH-wildtype
high-grade glioma could yield an excellent RT response,
irrespective of the adverse features of gliomatosis or the
involvement of the SVZ. Owing to the limited number
of ATM mutations in high-grade glioma, a further valid-
ation in a larger cohort, even including patients under
gross total removal status, is needed to identify the prog-
nostic value of ATM mutations. Therefore, we have initi-
ated a multicenter cohort study with Korean Radiation
Oncology Group (Protocol No. KROG 19–11). Further
preclinical and prospective clinical studies are warranted
to elucidate the role of large field RT in patients with
ATM mut(+) and the effect of the combination of RT
and ATM inhibitors during the course of RT in IDH-
wildtype high-grade glioma.
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